Starpharma CEO Cheryl Maley joined Steve Darling from Proactive to discuss the company’s recent momentum in oncology development and strategic partnerships, underscoring growing commercial and clinical interest in its proprietary dendrimer-based drug delivery platform.

Maley explained that Starpharma’s technology enables more efficient and targeted drug delivery and has demonstrated significant benefits in oncology. The dendrimer platform is designed to improve the therapeutic performance of medicines while reducing side effects and toxicity, and can be applied across a wide range of molecules, from small-molecule drugs to complex antibodies.

She confirmed that Starpharma signed two major agreements in 2025. The first was an exclusive licensing deal with Genentech, valued at up to 860 million Australian dollars plus royalties, focused on a specific and undisclosed area of oncology. The second was a research collaboration with Radiopharm Theranostics that includes an option for exclusivity.

In parallel with its partnering activity, Starpharma continues to advance its internal development programs, particularly in radiotherapy. Maley said the company is targeting the entry of these assets into clinical trials in 2026. Starpharma also maintains a strategic relationship with private equity group Medicxi through a joint venture structure.

On the commercial front, Maley highlighted the company’s plans to grow revenue from its two registered products, VIRALEZE and VivaGel, which are now available in approximately 35 countries. She added that Starpharma currently has three Phase 2 assets in development, with two of those programs actively targeted for licensing.

#proaxctiveinvestors #starpharma #asx #spl #otc #sphry #OncologyInnovation #DrugDeliveryTech #BiotechNews #CherylMaley #GenentechPartnership #Radiopharm #VIRALEZE #VivaGel #DendrimerTechnology #PharmaPartnerships #ASXBiotech #ClinicalTrials #BiopharmaUpdates #Medicxi